
Sign up to save your podcasts
Or
In this week’s View, Dr. Eagle looks colchicine versus placebo in reducing major adverse cardiovascular (CV) events including CV death or myocardial infarction in patients with vascular disease. He then discusses insights from the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry in terms of direct oral anticoagulants (DOACs) versus warfarin after transcatheter aortic valve replacement (TAVR). Finally, Dr. Eagle explores the use of conduction system pacing (CSP) rather than biventricular pacing (BiVP) in achieving clinical and echocardiographic response.
Subscribe to Eagle’s Eye View
4.7
127127 ratings
In this week’s View, Dr. Eagle looks colchicine versus placebo in reducing major adverse cardiovascular (CV) events including CV death or myocardial infarction in patients with vascular disease. He then discusses insights from the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry in terms of direct oral anticoagulants (DOACs) versus warfarin after transcatheter aortic valve replacement (TAVR). Finally, Dr. Eagle explores the use of conduction system pacing (CSP) rather than biventricular pacing (BiVP) in achieving clinical and echocardiographic response.
Subscribe to Eagle’s Eye View
129 Listeners
324 Listeners
161 Listeners
862 Listeners
493 Listeners
31 Listeners
279 Listeners
87 Listeners
1,090 Listeners
61 Listeners
39 Listeners
185 Listeners
349 Listeners
426 Listeners
37 Listeners